The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Regulatory News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on Share Consolidation & Admission Warrants

2 Jun 2021 09:32

RNS Number : 5579A
Motif Bio PLC
02 June 2021
 

 

2 June 2021

 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH AFRICA, THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

 

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN MOTIF BIO PLC OR ANY OTHER ENTITY IN ANY JURISDICTION.

 

 

Motif Bio plc

("Motif" or the "Company")

 

Update on Share Consolidation and Admission Warrants

 

Motif Bio plc (AIM: MTFB), which has been reclassified as an AIM Rule 15 cash shell, provides an update on the Share Consolidation and Admission Warrants that were detailed in its announcement of 26 May 2021.

 

The Company's current issued share capital of 654,991,023 will be adjusted through a proposed Share Consolidation to 2,977,231 New Ordinary Shares. The Company will issue 27,502,645 Consideration Shares for the proposed acquisition of BiVictriX (the "Acquisition"). On a primary basis, prior to the concurrent £10.1 million Fundraising, the Company will have 30,479,876 New Ordinary shares outstanding and issued.

 

As additional consideration, Admission Warrants over 1,488,615 New Ordinary Shares are to be issued for the benefit of existing Motif shareholders.  

 

The Admission Warrants will be granted on the basis of one Admission Warrant per two New Ordinary Shares held immediately prior to completion of the Acquisition, with an exercise price of 30 pence and valid for 180 days following Admission which is expected to be on or around 8.00 a.m. on 15 June 2021.

 

The Admission Warrants will not be listed or admitted to trading, are not freely transferable and will be issued to existing Motif shareholders in certificated form by 25 June 2021.

 

The Acquisition details, as provided above, are all conditional on Shareholder support of all Resolutions at the General Meeting. For additional information on the Acquisition, please see the Admission Document which is posted on the Company's website (www.motifbio.com).

 

As all Resolutions to be voted on at the General Meeting are conditional, all Resolutions must be approved by shareholders for the Acquisition to proceed. Motif Bio plc will not be able to continue operations in the absence of this Acquisition. As a result, if all Resolutions are not approved by shareholders, it is expected that Motif's shares would be de-listed from the AIM market and Shareholders would receive no further value.

 

 

Expected Timetable of Principal Events

 

 Time and date of the General Meeting

12.00 p.m. on 14 June 2021

Announcement of the result of the General Meeting

14 June 2021

Record date for the issue of the Admission Warrants

6.00 p.m. on 14 June

Ex-date of the issue of the Admission Warrants

15 June 2021

Despatch of Admission Warrant certificates

By 25 June 2021

 

 

The Admission Document and further information on the Company can be found on Motif's website at: www.motifbio.com

Capitalised terms used in this announcement carry the same meanings as those ascribed to them in the Company's Admission Document dated 26 May 2021 and/or the Company's announcement of 26 May 2021, unless the context requires otherwise.

For further information please contact:

 

Motif Bio plc

 

ir@motifbio.com

Jonathan Gold (Non-Executive Director)

 

 

 

SP Angel Corporate Finance LLP (NOMAD & BROKER)

+44 (0) 20 3470 0470

David Hignell/Caroline Rowe (Corporate Finance)

 

Vadim Alexandre/Rob Rees (Sales & Broking)

 

 

 

Walbrook PR Ltd. (UK FINANCIAL PR & IR)

+44 (0) 20 7933 8780

Paul McManus/ Lianne Cawthorne

motifbio@walbrookpr.com

 

 

 

 

Forward-Looking Statements

This announcement may contain forward-looking statements. Words such as "expects", "anticipates", "may", "should", "would", "could", "will", "intends", "plans", "believes", "targets", "seeks", "estimates", "aims", "projects", "pipeline" and variations of such words and similar expressions are intended to identify such forward-looking statements and expectations. These statements are not guarantees of future performance or the ability to identify and consummate transactions and involve certain risks, uncertainties, outcomes of negotiations and due diligence and assumptions that are difficult to predict, qualify or quantify. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements or expectations. Among the factors that could cause actual results to differ materially are: the general economic climate, competition, interest rate levels, loss of key personnel, the result of legal and commercial due diligence and changes in the legal or regulatory environment.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDSSSSAEEFSEEM
Date   Source Headline
22nd Jul 20154:32 pmRNSFDA QIDP Designation
22nd Jul 20157:00 amRNSFinal condition of £22m placing satisfied
20th Jul 20157:00 amRNSExercise of Options
17th Jul 20157:00 amRNSFDA QIDP Designation for Iclaprim for HABP
15th Jul 20157:00 amRNSNew Addition to Scientific Advisory Board
10th Jul 20153:29 pmRNSExercise of Options
10th Jul 20151:37 pmRNSResult of General Meeting
23rd Jun 20158:47 amRNSPartner Company raises £22 million
23rd Jun 20157:00 amRNSPlacing to raise £22 million and Change of Adviser
9th Jun 20157:00 amRNSAudited Non-Statutory Financial Statements
4th Jun 20154:41 pmRNSSecond Price Monitoring Extn
4th Jun 20154:35 pmRNSPrice Monitoring Extension
1st Jun 20157:00 amRNSMotif partners with Leading Global CRO
28th May 20157:00 amRNSFDA Meeting Minutes Confirming Iclaprim Phase III
12th May 20157:01 amRNSMOTIF SELECTED TO PRESENT AT BIOTECH EVENT
7th May 20157:00 amRNSFunding Strategy Update
15th Apr 20157:01 amRNSFDA Results
15th Apr 20157:00 amRNSFDA agree to enter clinical development programme
2nd Apr 20157:00 amRNSFirst Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.